日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia

新型双靶向PI3Kδ/BRD4抑制剂SF2535在B细胞急性淋巴细胞白血病中的临床前评价

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2021.766888
Ruan, Yongsheng; Kim, Hye Na; Ogana, Heather A; Wan, Zesheng; Hurwitz, Samantha; Nichols, Cydney; Abdel-Azim, Nour; Coba, Ariana; Seo, Seyoung; Loh, Yong-Hwee Eddie; Gang, Eun Ji; Abdel-Azim, Hisham; Hsieh, Chih-Lin; Lieber, Michael R; Parekh, Chintan; Pal, Dhananjaya; Bhojwani, Deepa; Durden, Donald L; Kim, Yong-Mi
B细胞
BRD4
白血病
细胞生物学
免疫/内分泌
发表日期：2021
文献求助 收藏

Characterizing the Motility of Chemotherapeutics-Treated Acute Lymphoblastic Leukemia Cells by Time-Lapse Imaging

利用延时成像技术表征化疗药物治疗的急性淋巴细胞白血病细胞的运动性

期刊:Cells
影响因子:5.2
doi:10.3390/cells9061470
Liu, Hsiao-Chuan; Gang, Eun Ji; Kim, Hye Na; Ruan, Yongsheng; Ogana, Heather; Wan, Zesheng; Bönig, Halvard; Shung, K Kirk; Kim, Yong-Mi
白血病
细胞生物学
发表日期：2020
文献求助 收藏

TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.

Galunisertib (LY2157299) 阻断 TGFβR1 可增强抗 GD2 抗体 Dinutuximab (ch14.18) 与自然杀伤细胞的抗神经母细胞瘤活性

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-16-1743
Tran Hung C, Wan Zesheng, Sheard Michael A, Sun Jianping, Jackson Jeremy R, Malvar Jemily, Xu Yibing, Wang Larry, Sposto Richard, Kim Eugene S, Asgharzadeh Shahab, Seeger Robert C
神经科学
细胞生物学
发表日期：2017
文献求助 收藏